December 14, 2024 08:53 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Pushpa 2 stampede: Allu Arjun walks out of jail, actor's lawyer slams delay in release | Donald Trump intends to end 'inconvenient' and 'very costly' Daylight Saving Time | Suchir Balaji: Indian-origin former OpenAI researcher found dead at US apartment | Bengaluru techie suicide: Karnataka Police issues summons to wife Nikita, her family members | French President Macron appoints centrist leader Francois Bayrou as new Prime Minister | Congress always prioritised personal interest over Constitution: Rajnath Singh | Jaishankar calls attack on Hindus in Bangladesh 'a source of concern' | Allu Arjun arrested over woman's death in stampede during Pushpa 2 premiere show | RBI receives bomb threat in Russian language, case filed | UP teenager kills mother, lives with body for 5 days
Photo courtesy: twitter.com/yogrishiramdev

SC issues contempt notice to Ramdev's Patanjali Ayurved, Acharya Balkrishna for misleading ads on medicines

| @indiablooms | Feb 28, 2024, at 04:16 am

New Delhi: The Supreme Court on Tuesday issued a show cause notice to Patanjali Ayurved and the company’s managing director Acharya Balkrishna for deviating from their promise to not make misleading claims in their product advertisements, media reports said.

The apex court put restrictions on the company co-founded by Yoga guru Baba Ramdev from circulating any advertisement with claims to cure illnesses such as high blood pressure, diabetes, fevers, epilepsy and lupus, which are mentioned in the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, Moneycontrol reported.

The court slammed the company and criticised the government in strong words.

“The entire country is being taken for a ride" and the government is "sitting with its eyes closed," it said, according to the report.

Pulling up the government for lack of action, the court directed it to submit a sworn statement detailing measures implemented to curb companies' dissemination of inaccurate medication representations through the media.

Patanjali and its staff received a warning against disseminating any misleading claims regarding their product's capacity to treat illnesses.

This directive was issued in response to a writ petition filed by the Indian Medical Association (IMA) over misleading advertisements by certain companies.

In November, Patanjali had promised to refrain from publishing ads that made false claims about its products and disparaged modern medicines and vaccinations.

However, despite this commitment, Patanjali continued to run such advertisements, as reported to the court.

In November 2023, the court warned Patanjali and said, "All false and misleading advertisements by Patanjali Ayurved have to stop immediately. This court will take such infractions very seriously and will consider imposing costs of up to Rs 1 crore on every product for which a false claim is made that it can cure a particular disease."

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.